Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-103 with Haloperidol or Risperidone in Schizophrenia
NCT00361166Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pimavanserin in schizophrenia (5 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Positive and Negative Symptom Scale. Started Aug 2005; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00361166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361166.